Hypogonadism was defined as a tT<300 ng/dL, or a documented diagnosis.RESULTS: A total of 36 men were included with a mean age was 58.2 years old (SD 10.4). The mean pre-treatment tT was 459.2 ng/ dL (SD 144.0), and 14 (39.9%) were hypogonadal, of whom 5 (35.7%) were receiving hormonal replacement therapy, 4 on testosterone and 1 on clomiphene. Mean pre-treatment curvature was 47.6 (SD 14.2) and mean post-treatment curvature was 27.8 (SD 10.7), for a mean improvement of 19.9 (40.1%) after a median of 4 cycles (2-8). Hypogonadism was significantly associated with more severe curvature, 54.6 among hypogonadal men compared to 43.2 among eugonadal men (p[0.03); however, baseline curvature and tT were not significantly associated (b[-0.03; R 2 [0.09; p[0.08). On linear regression analysis, tT did not significantly predict improvement in degrees (b[-0.02; R 2 [0.06; p[0.14) (Figure 1) or percent (b[0.0; R 2 [0.05; p[0.18). Improvement in neither degrees nor percent differed by hypogonadal status (p[0.14 and p[0.69, respectively). Number of cycles did significantly predict greater improvement in curvature on both univariate and multivariate analyses (b[5.7; R 2 [0.34; p<0.01).CONCLUSIONS: While hypogonadism is associated with more severe curvature, neither total testosterone nor hypogonadism is associated with degree of improvement after CCh treatment. Men should be offered CCh therapy according to guidelines independent of gonadal status.